The past week saw four IPOs produce insignificant returns. All four deals finished the week at or above the offer price, but none gained more than 5%. The first bank IPO of 2016, Argentina-based Grupo Supervielle dual listed in New York and Buenos Aires; its...read more
Merus, which is developing bispecific antibody treatments for solid tumors, raised $55 million by offering 5.5 million shares at $10. It originally planned to offer 4.3 million shares at a range of $14 to $16. Its new market cap of $158 million is a 29% discount...read more
There are four companies set to debut in the week ahead, but only one company with substantial revenue and profit - small-cap Argentinian bank Grupo Supervielle (SUPV). Three additional deals launched and are set to price in May including the...read more
Merus, which is developing bispecific antibody treatments for solid tumors, announced terms for its IPO on Monday. The Utrecht, Netherlands-based company plans to raise $65 million by offering 4.3 million shares at a price range of $14 to $16. Insiders...read more
US IPO Weekly Recap: A LatAm bank and three minor health care IPOs struggle
The past week saw four IPOs produce insignificant returns. All four deals finished the week at or above the offer price, but none gained more than 5%. The first bank IPO of 2016, Argentina-based Grupo Supervielle dual listed in New York and Buenos Aires; its...read more
Cancer therapies get a price cut: Merus prices upsized IPO well below the range at $10
Merus, which is developing bispecific antibody treatments for solid tumors, raised $55 million by offering 5.5 million shares at $10. It originally planned to offer 4.3 million shares at a range of $14 to $16. Its new market cap of $158 million is a 29% discount...read more
US IPO Week ahead: Four more IPOs set up May 2016 to be most active month YTD
There are four companies set to debut in the week ahead, but only one company with substantial revenue and profit - small-cap Argentinian bank Grupo Supervielle (SUPV). Three additional deals launched and are set to price in May including the...read more
Novartis, J&J and Pfizer-backed Merus sets terms for $65 million IPO
Merus, which is developing bispecific antibody treatments for solid tumors, announced terms for its IPO on Monday. The Utrecht, Netherlands-based company plans to raise $65 million by offering 4.3 million shares at a price range of $14 to $16. Insiders...read more